Recent studies performed on tumour models showed that IDO inhibition and thereby decreased formation of tryptophan metabolites could significantly enhance the antitumour activity of various chemotherapeutic and immunotherapeutic agents (48). This evidence concerns the gene IDO1 and neoplasm.